Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04590014 · ClinicalTrials.gov registry record · NA
Clinical Efficacy in Relief of Dyspnea by HVNI: Evaluation of New Device Equivalence
A NA study, sponsored by Vapotherm.
- Terminated
- Registry status
- NA
- Development phase
- 5
- Enrollment target
NCT04590014: Clinical Trial NA study, sponsored by Vapotherm.
NCT04590014 is a NA study that was terminated before completion, run by Vapotherm. The registered enrollment target is 5 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04590014, a NA study, was terminated before completion, sponsored by Vapotherm.
- TERMINATED
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study will evaluate the ability of a new High Velocity Nasal Insufflation \[HVNI\] device design to effect ventilation and related physiological responses relative to the current HVNI device design.
Primary Outcome
Patient's subjective assessment of their dyspnea, rated as a modified Borg score on a scale from 0 to 10. Higher scores indicate a worse outcome.
Interventions
- DEVICE Conventional Precision Flow
- DEVICE HVNI HVT2.0 Device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2022-01-12 |
| Est. Completion | 2022-07-15 |
| Phase | NA |
Why NCT04590014 stopped before completion
NCT04590014 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which Conventional Precision Flow is the first listed.
NCT04590014 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04590014 about?
NCT04590014 is a clinical study titled "Clinical Efficacy in Relief of Dyspnea by HVNI: Evaluation of New Device Equivalence". This study will evaluate the ability of a new High Velocity Nasal Insufflation \[HVNI\] device design to effect ventilation and related physiological responses relative to the current HVNI device design.
What is the current status of trial NCT04590014?
This trial is currently terminated. It is a NA study. The enrollment target is 5 participants. The study started on 2022-01-12. Estimated completion is 2022-07-15.
What interventions are being tested in trial NCT04590014?
The interventions under investigation include: Conventional Precision Flow (DEVICE), HVNI HVT2.0 Device (DEVICE).
Who is sponsoring clinical trial NCT04590014?
This trial is sponsored by Vapotherm, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04590014's enrollment target sits among peer trials
5 1988th of 2000 higher than 5 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI